|Mr. Gary Jonathan Phillips BPharm, MBA||CEO & Director||N/A||N/A||56|
|Mr. David Morris McGarvey BA, CA, CPA||CFO & Company Sec.||N/A||N/A||61|
|Mr. Wolfgang G. Jarolimek B.Sc. Ph.D.||Head of Drug Discovery||N/A||N/A||53|
|Dr. Brett Charlton MBBS Ph.D.||Medical Director||N/A||N/A||61|
|Ms. Kristen Morgan BSc,PGDipBusAdmin,MMedSc||Exec. Officer||157.43k||N/A||45|
Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to help doctors in diagnosing and managing asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The companys amine oxidase drug development programs include selective LOXL2 inhibitor for pulmonary fibrosis, non-alcoholic steatohepatitis, and liver and kidney fibrosis; mixed LOXL/LOXL2 inhibitor for cancer, severe liver and kidney fibrosis, and tissue scarring; semicarbazide-sensitive amine oxidase (SSAO)/MAO-B inhibitor for neuro inflammation; and SSAO/MPO inhibitor for lung inflammation, asthma, and chronic obstructive pulmonary disease. It has a research collaboration with Woolcock Institute of Medical Research to develop a novel inhalation therapy for the treatment of cystic fibrosis. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Pharmaxis Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.